Vanguard Group Inc Trevi Therapeutics, Inc. Transaction History

Vanguard Group Inc

$5.12 Trillion
Q2 2024

A detailed history of Vanguard Group Inc transactions in Trevi Therapeutics, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 2,437,451 shares of TRVI stock, worth $8.12 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

2,437,451

Previous 2,303,648 5.81%

Holding current value

$8.12 Million

Previous $7.95 Million 8.61%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	BUY	$2.44 - $3.36 $326,479 - $449,578	133,803 Added 5.81%	2,437,451 $7.26 Million
Q1 2024 May 10, 2024	BUY	$1.3 - $3.7 $78,323 - $222,921	60,249 Added 2.69%	2,303,648 $7.95 Million
Q4 2023 Feb 14, 2024	BUY	$1.06 - $2.05 $302,655 - $585,324	285,524 Added 14.58%	2,243,399 $3.01 Million
Q3 2023 Nov 14, 2023	BUY	$2.11 - $2.47 $94,133 - $110,194	44,613 Added 2.33%	1,957,875 $4.27 Million
Q2 2023 Aug 14, 2023	BUY	$1.8 - $3.44 $744,319 - $1.42 Million	413,511 Added 27.57%	1,913,262 $4.57 Million
Q1 2023 May 15, 2023	BUY	$1.69 - $2.97 $101,667 - $178,669	60,158 Added 4.18%	1,499,751 $2.77 Million
Q4 2022 Feb 10, 2023	BUY	$1.61 - $2.42 $185,497 - $278,822	115,216 Added 8.7%	1,439,593 $2.78 Million
Q3 2022 Nov 14, 2022	BUY	$1.54 - $4.28 $1.67 Million - $4.65 Million	1,087,437 Added 458.95%	1,324,377 $2.04 Million
Q2 2022 Aug 12, 2022	BUY	$1.8 - $3.39 $151,396 - $285,129	84,109 Added 55.03%	236,940 $666,000
Q1 2022 May 13, 2022	BUY	$0.46 - $2.48 $4,958 - $26,734	10,780 Added 7.59%	152,831 $336,000
Q4 2021 Feb 14, 2022	BUY	$0.68 - $1.5 $3,741 - $8,253	5,502 Added 4.03%	142,051 $111,000
Q3 2021 Nov 12, 2021	BUY	$1.29 - $2.18 $4,300 - $7,268	3,334 Added 2.5%	136,549 $192,000
Q2 2021 Aug 13, 2021	BUY	$2.0 - $2.76 $266,430 - $367,673	133,215 New	133,215 $300,000

Others Institutions Holding TRVI

# of Institutions

Shares Held

54.3M

Call Options Held

15.6K

Put Options Held

View Full List

About Trevi Therapeutics, Inc.

Ticker TRVI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 58,322,500
Market Cap $194M
Description
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase IIb/III clinical trial for the treatment of chronic pruritu...

More about TRVI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.

Account

Vanguard Group Inc Trevi Therapeutics, Inc. Transaction History